Drug Profile
ABBV 2B04
Alternative Names: 2B04; ABBV-2B04; AbbVie 2B04; mAb 2B04Latest Information Update: 28 Jan 2024
Price :
$50
*
At a glance
- Originator Washington University
- Developer AbbVie
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical COVID 2019 infections
Most Recent Events
- 28 Jan 2024 No recent reports of development identified for phase-I development in COVID-2019-infections(Combination therapy) in Hungary (IV, Infusion)
- 28 Jan 2024 No recent reports of development identified for phase-I development in COVID-2019-infections(Combination therapy) in Israel (IV, Infusion)
- 28 Jan 2024 No recent reports of development identified for phase-I development in COVID-2019-infections(Combination therapy) in Netherlands (IV, Infusion)